Wei Xu

Mr. Wei Xu is a Partner at Decheng Capital and has been with the firm since 2017. He is currently serving on the boards of Accuragen, AnHeart Therapeutics, Centricity Vision, Ketai Medical, MDCO, and Mynosys.

At Decheng, Mr. Xu focuses on investments in biotechnology and medical device companies in China and US. Prior to joining Decheng, Mr. Xu was Managing Director of Denlux Capital and served on the boards of Cirina (acquired by GRAIL), BEST (NYSE: BSTI), and SINOMED (688108.CH). His investment portfolio also includes Shengda (002259.SZ), SCYAHUA (002497.SZ), Dadifengyuan (acquired by Yonker, 300187.SZ), SZJECH (acquired by Orient Scape, 002310.SZ), NCM China (acquired by Tencent), Hsyuntai, Baoji Clinic, Immune-Onc., etc.

Mr. Xu received his Masters's degree in Economics from the University of Oslo, and a BS degree from the College of Biomedical Engineering & Instrument Science from Zhejiang University.